For US drug operations, cold chain compliance requires evidence appropriate to the product and regulated activity. Do not treat FDA requirements as one universal temperature range or a packaging certification. Establish the applicable obligations, then connect them to controlled procedures, distribution records and product-specific quality decisions.
Define the US drug scope
Identify the drug product and presentation, the licensed activity and the organizations handling it. Use the authorized product information and the responsible quality unit’s instructions to establish required conditions. Biological products and other categories may have additional requirements; assess their actual scope.
Food transport rules and drug supply-chain rules should not be combined into one undifferentiated checklist. A business handling both needs controls relevant to each product and activity.
Separate temperature control from product tracing
21 CFR 211.142: drug warehousing procedures requires written warehousing procedures covering quarantine before quality-control release and suitable storage conditions. 21 CFR 211.150: drug distribution procedures addresses written distribution procedures and lot-distribution information supporting recall.
FDA: DSCSA product tracing questions explains product tracing for most human prescription drugs in finished form. Tracing identity and transactions is a distinct task from demonstrating acceptable temperature exposure.
A traceable lot can still have a temperature excursion. Conversely, a satisfactory temperature record does not establish that applicable product-tracing obligations have been met. Assess both where they apply.
Connect the records for one shipment
| Evidence area | Review question |
|---|---|
| Product instruction | Which conditions apply to this exact presentation? |
| Release status | Was the product authorized for distribution? |
| Packing record | Which components and preparation were actually used? |
| Custody record | Who handled the load and where did it wait? |
| Temperature evidence | Does it cover the relevant exposure and identified locations? |
| Deviation decision | Who assessed the incident and authorized disposition? |
This is an organizing checklist, not a complete statement of every FDA obligation. Keep each record linked to shipment and lot identity so the quality team can investigate the actual event.
Helpful decision tools
Check the details before you choose packaging
These quick tools can help you compare route risk, sizing needs, coolant choices, and packaging details before you request a quote.
Compliance Checklist Generator
Build a practical checklist for packaging review, shipping, and documentation.
Build checklistCoolant & PCM Reference
Compare coolant and PCM options when a route needs added temperature support.
Compare optionsRoute Risk Checker
Review lane conditions before selecting packaging for real operating requirements.
Check route riskManage an excursion without inventing a limit
- Identify and segregate the affected product as required.
- Retain the full temperature trace and relevant handling record.
- Check device suitability, placement and data completeness.
- Document the duration and circumstances of the departure.
- Obtain the authorized product-specific assessment.
- Record disposition and any corrective action.
Do not invent a safe number of hours outside range, or assume returning the product to a refrigerator restores its quality. Generic supplier claims cannot replace the responsible product assessment.
Review recurring causes such as preparation errors, receiving delays or lost records. Choose corrective actions tied to the observed problem and verify their effectiveness through the applicable quality process.
Frequently asked questions
Does FDA require every medicine to stay at 2–8°C?
No single range covers all medicines. Use the requirements for the actual product.
Is DSCSA a temperature-monitoring standard?
No. Its product-tracing requirements address a different part of supply-chain control.
Does buying a qualified shipper complete compliance?
No. Its evidence must fit the intended use, and applicable procedures and records remain necessary.
Keep the scope clear across borders
Use the pharmaceutical lane compliance map for jurisdictional comparisons, and the medicine conditions guide for product-specific transport planning.
